Haematologists have been using liposomal amphotericin-B (L-AMB) since 1993 and despite the introduction of several novel antifungal agents over the past decade, their propensity to prescribe L-AMB remains unchanged. Although antifungal guidelines strongly recommend voriconazole as the drug of choice in the treatment of probable and proven invasive fungal disease (IFD), L-AMB is widely used in the real life because of its several advantages in terms of wide anti-mould spectrum, tolerability and efficacy. Furthermore, the concept that L-AMB is endowed with immune-modulating effects, which may have a role in fighting IFD, represent another reason for its use in patients who do not tolerate an excess of inflammation. Finally, given its tolerability and safety, L-AMB is an ideal partner for combining therapy, particularly with echinocandins with which shares the immunological properties that result in a synergistic effect.

Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use / Aversa, Franco; Busca, Alessandro; Candoni, Anna; Cesaro, Simone; Girmenia, Corrado; Luppi, Mario; Nosari, Anna Maria; Pagano, Livio; Romani, Luigina; Rossi, Giuseppe; Venditti, Adriano; Novelli, Andrea. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 29:3(2017), pp. 131-143. [10.1080/1120009X.2017.1306183]

Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use

Candoni, Anna;LUPPI, Mario;
2017

Abstract

Haematologists have been using liposomal amphotericin-B (L-AMB) since 1993 and despite the introduction of several novel antifungal agents over the past decade, their propensity to prescribe L-AMB remains unchanged. Although antifungal guidelines strongly recommend voriconazole as the drug of choice in the treatment of probable and proven invasive fungal disease (IFD), L-AMB is widely used in the real life because of its several advantages in terms of wide anti-mould spectrum, tolerability and efficacy. Furthermore, the concept that L-AMB is endowed with immune-modulating effects, which may have a role in fighting IFD, represent another reason for its use in patients who do not tolerate an excess of inflammation. Finally, given its tolerability and safety, L-AMB is an ideal partner for combining therapy, particularly with echinocandins with which shares the immunological properties that result in a synergistic effect.
2017
24-mar-2017
29
3
131
143
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use / Aversa, Franco; Busca, Alessandro; Candoni, Anna; Cesaro, Simone; Girmenia, Corrado; Luppi, Mario; Nosari, Anna Maria; Pagano, Livio; Romani, Luigina; Rossi, Giuseppe; Venditti, Adriano; Novelli, Andrea. - In: JOURNAL OF CHEMOTHERAPY. - ISSN 1120-009X. - 29:3(2017), pp. 131-143. [10.1080/1120009X.2017.1306183]
Aversa, Franco; Busca, Alessandro; Candoni, Anna; Cesaro, Simone; Girmenia, Corrado; Luppi, Mario; Nosari, Anna Maria; Pagano, Livio; Romani, Luigina; Rossi, Giuseppe; Venditti, Adriano; Novelli, Andrea
File in questo prodotto:
File Dimensione Formato  
aversa2017.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 994.18 kB
Formato Adobe PDF
994.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1135950
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 26
social impact